4.5 Review

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

Related references

Note: Only part of the references are listed.
Article Oncology

Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study

William E. Winter et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Review Oncology

Experience with bevacizumab in the management of epithelial ovarian cancer

Robert A. Burger

JOURNAL OF CLINICAL ONCOLOGY (2007)

Review Oncology

Mechanisms of adverse effects of anti-VEGF therapy for cancer

T. Kamba et al.

BRITISH JOURNAL OF CANCER (2007)

Article Oncology

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy

Hiroaki Itamochi et al.

MOLECULAR CANCER THERAPEUTICS (2007)

Review Oncology

Novel therapeutic agents in ovarian cancer

R. Agarwal et al.

Article Obstetrics & Gynecology

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary

H Itamochi et al.

OBSTETRICS AND GYNECOLOGY (2002)

Article Oncology

Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary

H Itamochi et al.

JAPANESE JOURNAL OF CANCER RESEARCH (2002)

Review Biochemistry & Molecular Biology

Apoptosis: A link between cancer genetics and chemotherapy

RW Johnstone et al.

Article Oncology

Survival among US women with invasive epithelial ovarian cancer

V McGuire et al.

GYNECOLOGIC ONCOLOGY (2002)

Article Oncology

p53 mutation is infrequent in clear cell carcinoma of the ovary

ESC Ho et al.

GYNECOLOGIC ONCOLOGY (2001)

Review Oncology

A family of drug transporters: The multidrug resistance-associated proteins

P Borst et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)